CN110945030A - 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法 - Google Patents

使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法 Download PDF

Info

Publication number
CN110945030A
CN110945030A CN201880048338.0A CN201880048338A CN110945030A CN 110945030 A CN110945030 A CN 110945030A CN 201880048338 A CN201880048338 A CN 201880048338A CN 110945030 A CN110945030 A CN 110945030A
Authority
CN
China
Prior art keywords
cell
cells
tregs
april
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880048338.0A
Other languages
English (en)
Chinese (zh)
Inventor
K·C·安德森
Y-T·泰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN110945030A publication Critical patent/CN110945030A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880048338.0A 2017-06-20 2018-06-20 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法 Pending CN110945030A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762522167P 2017-06-20 2017-06-20
US62/522,167 2017-06-20
US201762573264P 2017-10-17 2017-10-17
US62/573,264 2017-10-17
US201862677265P 2018-05-29 2018-05-29
US62/677,265 2018-05-29
PCT/US2018/038490 WO2018236995A2 (en) 2017-06-20 2018-06-20 Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction

Publications (1)

Publication Number Publication Date
CN110945030A true CN110945030A (zh) 2020-03-31

Family

ID=64735842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880048338.0A Pending CN110945030A (zh) 2017-06-20 2018-06-20 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法

Country Status (7)

Country Link
US (1) US12005073B2 (enExample)
EP (1) EP3642243A4 (enExample)
JP (1) JP2020524149A (enExample)
CN (1) CN110945030A (enExample)
AU (1) AU2018289493B2 (enExample)
CA (1) CA3064632A1 (enExample)
WO (1) WO2018236995A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368262A (zh) * 2020-09-03 2021-09-10 上海易慕峰生物科技有限公司 通过实体肿瘤转移动物模型获取中间结果的方法
CN114147343A (zh) * 2021-12-08 2022-03-08 西安中科微精光子制造科技有限公司 一种激光加工方法、系统及计算机存储介质
WO2022048314A1 (zh) * 2020-09-03 2022-03-10 上海易慕峰生物科技有限公司 针对循环肿瘤细胞的免疫杀伤细胞在实体瘤治疗中的应用
CN118126196A (zh) * 2024-03-06 2024-06-04 中国医学科学院基础医学研究所 一种具有包含taci融合蛋白的基因工程化外泌体及其制备方法和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11435370B2 (en) * 2017-01-16 2022-09-06 Shimadzu Corporation Data analying device and program for data analysis
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. PROCESSES FOR MODULATION OF REGULATORY T-LYMPHOCYTES, REGULATORY B-LYMPHOCYTES AND IMMUNE RESPONSES USING MODULATORS OF THE AVRIL-TACI INTERACTION
EP3976100A4 (en) * 2019-05-31 2023-07-12 Medimmune, LLC POLYTHERAPY
IL297981A (en) 2020-05-08 2023-01-01 Alpine Immune Sciences Inc April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
CA3194116A1 (en) * 2020-09-29 2022-04-07 Mingji Dai Curcusone diterpenoids and uses thereof
CN113278619B (zh) * 2021-07-19 2021-10-15 广东省农业科学院动物科学研究所 双sgRNA、基因敲除载体、基因敲除STING基因的猪成纤维细胞系及其构建方法
CN120843525B (zh) * 2025-09-23 2025-12-09 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 特异结合人april的中和核酸适体及其在抑制抗体分泌中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087979A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
CN101323643A (zh) * 2007-06-15 2008-12-17 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011047121A1 (en) * 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
CN102585016A (zh) * 2012-03-06 2012-07-18 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
WO2016110587A1 (en) * 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. PROCESSES FOR MODULATION OF REGULATORY T-LYMPHOCYTES, REGULATORY B-LYMPHOCYTES AND IMMUNE RESPONSES USING MODULATORS OF THE AVRIL-TACI INTERACTION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087979A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
CN101323643A (zh) * 2007-06-15 2008-12-17 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011047121A1 (en) * 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
CN102585016A (zh) * 2012-03-06 2012-07-18 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
WO2016110587A1 (en) * 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Altered april binding antibodies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHIH-HANG ANTHONY TANG 等: "Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells", CANCER RESEARCH, vol. 76, no. 8, pages 2137 - 2152, XP055451857, DOI: 10.1158/0008-5472.CAN-15-1885 *
GANG YU 等: "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity", NATURE IMMUNOLOGY, vol. 1, no. 3 *
HANS-PETER HARTUNG 等: "Atacicept: targeting B cells in multiple sclerosis", THER ADV NEUROL DISORD, vol. 3, no. 4, pages 205 - 216, XP055568463, DOI: 10.1177/1756285610371146 *
JOHN DULOS 等: "Bion-1301: A Novel Fully Blocking APRIL Antibody for the Treatment of Multiple Myeloma", BLOOD, vol. 128, no. 22 *
张健锋;毛振彪;: "APRIL及其受体在消化系肿瘤中的作用研究进展", 国际消化病杂志, no. 05, pages 336 - 338 *
陆烈, 蔡洪培: "APRIL对肿瘤细胞增殖作用的研究进展", 中国肿瘤生物治疗杂志, no. 03, pages 217 - 219 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368262A (zh) * 2020-09-03 2021-09-10 上海易慕峰生物科技有限公司 通过实体肿瘤转移动物模型获取中间结果的方法
WO2022048314A1 (zh) * 2020-09-03 2022-03-10 上海易慕峰生物科技有限公司 针对循环肿瘤细胞的免疫杀伤细胞在实体瘤治疗中的应用
CN114147343A (zh) * 2021-12-08 2022-03-08 西安中科微精光子制造科技有限公司 一种激光加工方法、系统及计算机存储介质
CN114147343B (zh) * 2021-12-08 2024-08-16 西安中科微精光子科技股份有限公司 一种激光加工方法、系统及计算机存储介质
CN118126196A (zh) * 2024-03-06 2024-06-04 中国医学科学院基础医学研究所 一种具有包含taci融合蛋白的基因工程化外泌体及其制备方法和应用
CN118126196B (zh) * 2024-03-06 2024-08-16 中国医学科学院基础医学研究所 一种具有包含taci融合蛋白的基因工程化外泌体及其制备方法和应用

Also Published As

Publication number Publication date
AU2018289493A1 (en) 2019-12-12
EP3642243A2 (en) 2020-04-29
CA3064632A1 (en) 2018-12-27
AU2018289493B2 (en) 2025-07-03
WO2018236995A3 (en) 2019-01-31
JP2020524149A (ja) 2020-08-13
WO2018236995A2 (en) 2018-12-27
US20210113605A1 (en) 2021-04-22
EP3642243A4 (en) 2021-04-28
US12005073B2 (en) 2024-06-11

Similar Documents

Publication Publication Date Title
AU2018289493B2 (en) Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
US10927410B2 (en) Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
WO2021247540A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
WO2021150925A1 (en) Uses of biomarkers for improving immunotherapy
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
US11740242B2 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
US12109266B2 (en) Modulating gabarap to modulate immunogenic cell death
EP3265825A1 (en) Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
US20200149042A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
CN114729052A (zh) 抗kir3dl3抗体和其用途
AU2019227641B2 (en) Methods for treating cancer using combinations of anti-BTNL2 and immune checkpoint blockade agents
US12050219B2 (en) Modulating biomarkers such as SPP to increase tumor immunity and improve the efficacy of cancer immunotherapy
US20220289854A1 (en) Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
HK40028190A (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
HK1242344A1 (en) Methods for identification t-cell exhaustion using cd39 biomarkers and modulators
HK1242344B (en) Methods for identification t-cell exhaustion using cd39 biomarkers and modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination